Climb Bio Secures $110M in Private Placement

By Chris Stiles • Tuesday, April 28 11:15 • Permanent Link

Climb Bio said it has entered into a private placement expected to bring in about $110.0 million in gross proceeds.

The company priced 9,481,000 shares of common stock at $9.50 each, and also sold pre-funded warrants for up to 2,106,000 shares at $9.4999 per warrant. The pre-funded warrants carry an exercise price of $0.0001 per share.

The financing was backed by both new and existing investors, including Adage Capital Partners, Adar1 Capital Management, Affinity Asset Advisors, Ally Bridge Group, Cormorant Asset Management, Driehaus Capital Management, Great Point Partners, RA Capital Management, Redmile, Sirenia Capital Management, Woodline Partners and other institutional investors.

Leerink Partners and Piper Sandler are serving as lead placement agents, with Raymond James, BTIG, Baird and H.C. Wainwright also acting as placement agents.

Climb Bio said the transaction is expected to close on or about April 29, 2026. The company also said it will file a registration statement with the SEC no later than 45 days after closing to register the resale of the shares and the shares issuable upon exercise of the pre-funded warrants. The market has reacted to these announcements by moving the company's shares 1.33% to a price of $9.14. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.